Thinking of taking your company public? Get our essential guide to a successful IPO. Download Now

Westicke Partners


ICR Westwicke Blog

The ICR Westwicke Blog is designed to deliver information and insights into the ever-changing world of healthcare communications.

Fine-Tune Your Investor Deck for Success, Part I

Posted on August 3rd, 2021. Posted by

Whether for a one-on-one at a conference or an IPO road show, your corporate presentation is a critical piece of your investor relations strategy. A PowerPoint deck may seem trivial compared to the entirety of your enterprise, but the investor presentation remains one of the most tangible and effective tools for building (and losing) investor trust and engagement.

While many healthcare company presentations successfully focus investors on key value drivers, just as many run into pitfalls that can betray the company’s intended message. Could your presentation be starting your investor interactions on the wrong foot?

In this two-part series, learn a few of the easiest ways to transform your presentation into something powerful. This first post focuses on two core content elements of your presentation: your investment summary and data. The second post will look at how visual elements play a role in your presentation’s effectiveness and simple steps you can take to improve them.

Craft and distill your story – especially on slide No. 1

Your presentation should tell a clear, integrated story, and that story should fit on one slide. Your road show or conference deck isn’t the place to detail every aspect of your business. Nearly every effective investor presentation we have seen starts and ends with a succinct and compelling investment summary (often simply titled “Investment Highlights”). Make sure you have a summary, and make sure it is solid. Stay close to the following structure:

  • Bullet 1: Describe your business succinctly to help focus your audience
  • Bullet 2: Discuss what is important about the market that you are focused on
  • Bullet 3: Describe key products (e.g., pipeline products, therapeutic area focus, technology/platform), along with any other complementary detail
  • Bullet 4: Include an additional highlight (e.g., IP strength, upcoming milestones, regulatory or reimbursement feature, partnership strategies)
  • Bullet 5: Include a financial highlight (e.g., attractive financial model, cash/runway, other guidance)

Do you feel your business has too many features to fit on one page? As true as that may be, if you can’t boil down your investment highlights to a page, investors will invariably do it for you — and often less favorably. Be proactive and bookend your deck with razor-sharp investment highlights.

Build credibility with clear and conservative data representations

Statistics and data — especially in healthcare and the life sciences — can make or break a stock. And yet, presentations of data are among the most common sources of investor distrust. Avoid these pitfalls to make sure your data inspires further digging, not disdain:

  • Cherry picking: One can argue that subset analyses and other post-hoc “interpretive” touches to data can serve a constructive purpose. But it sends the wrong message if the majority of your data slides — and consequently, the bulk of the story — is dependent on them. Make a point of showing results for entire pre-defined study populations whenever possible.
  • Unclear study design or objective: Your analysts and investors should not have to guess your studies’ primary endpoints and objectives. While you may want to highlight one particular aspect of your results, do not withhold the original design details and endpoints. Showing that a study did not meet its primary objective or may have had enrollment anomalies, for example, is not nearly as destructive to your efforts as giving the impression that you are hiding those details.
  • Cross-study comparisons: While it’s convenient and interesting to compare your drug’s clinical data with the results of a competitor, you may end up inviting further scrutiny or skepticism to produce a chart that suggests too much. Be wary of claiming something like superiority when your studies were not designed to do so, or of placing a data point from a separate study on the same chart or diagram as your own. Analysts and investors may ultimately do such exercises on their own to determine your commercial positioning. And in many respects, that’s just fine. It is better for charts with this more casual science to appear on their documents than your own.
  • Poor chart type selection: Pie charts with too many slices, bar charts with illegible labels or poorly grouped columns — these are common data presentation pitfalls that can often be remedied with just a few clicks in Excel. Make sure the visual arrangement is designed to best communicate the takeaway message.

There are countless ways to improve the content of your presentation materials, but these are among the easiest and quickest steps you can take to earn an investor’s interest and trust. Our next post will share some additional guidelines on your presentation’s visuals and graphics.

For additional insight on how to make the most of investor meetings — whether virtual or in person — read our eBook, “How to Prepare for Successful Investor Meetings.”

Westwicke Logo

ICR Westwicke is the largest healthcare focused investor relations firm in the country. We provide customized investor relations programs and independent capital markets advice to small and mid-cap healthcare companies.

View full bio   |   Other posts by ICR Westwicke

Leave a Reply

Your email address will not be published. Required fields are marked *

Have News to Release?

Find out whether you should file a Form 8-K, issue a press release, or do both by using our easy-to-reference chart, “Form 8K vs. Press Release: What’s the Difference?

Our Locations